Dr. Rosmarin is the Chair of the Department of Dermatology at Indiana University and a clinical investigator. He previously served as the Vice-Chair for Research and Education at Tufts Medical Center focusing on clinical trials for inflammatory disorders of the skin. For his training, Dr. Rosmarin went to medical school at NYU, dermatology residency at Boston University-Tufts Combined training program, and fellowship at Brigham and Women’s Hospital. Dr. Rosmarin joined Tufts Medical Center in 2013 focusing as a clinical trial investigator. In 2016, Dr. Rosmarin became the Director of the Clinical Trials Unit in the Department of Dermatology at Tufts Medical Center. Notably, Dr. Rosmarin has served as the principal investigator for multiple investigator initiated trials for a topical JAK inhibitor for vitiligo, the use of an oral JAK inhibitor for discoid lupus, and for an anti-IL17 antibody to treat hidradenitis suppuritiva. These studies have resulted in Dr. Rosmarin becoming the PI for a multicentered trial evaluating topical ruxolitinib in vitiligo, which led to the first ever FDA indication for repigmenting vitiligo. Dr. Rosmarin is the first to use dupilumab for bullous pemphigoid which is now in a phase 3 program for an indication. Clinically Dr. Rosmarin is nationally recognized and serves as a referral for physicians with difficult to manage inflammatory diseases such as atopic dermatitis. Dr. Rosmarin educates medical students, residents, and research fellows. He served as Residency Program Director from 2016 to 2020 in which time he expanded the Tufts Medical Residency Program from nine positions to twelve residents and mentors faculty in education and research.
Kampen-Norins Scholar in Dermatology - 2023